Alfa Cytology Launches Full-Scale Research Services for Pancreatic Cancer to Achieve Preclinical Safety Assessment

April 20, 2024

Alfa Cytology, a premier tumor microenvironment research outsourcing service provider, has recently upgraded pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations.

Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. A recent study finds that the incidence rate of PC has been increasing each year, especially in people over 45 years old. Even young patients suffering from PC are showing a significant increase compared to a decade ago, and the malignancy is also higher than before, resulting in a worse prognosis.

To realize preclinical prediction and diagnosis of PC, Alfa Cytology provides a variety of services (molecular expertise of PC, detection & diagnosis of PC, and treatment strategy of PC in full tracking support). The range of PC basic research services includes PC pathology research, PC cell research, PC stem cell research, PC tumor model, and more. Additionally, Alfa Cytology is committed to exploring drug development services for pancreatic cancer.

“The new drug development services focus on the hotspot of PC tumor. We are pleased to develop small molecule drugs and peptide drugs for PC because they are the most promising and potential anti-pancreatic cancer drugs,” said the operation manager of Alfa Cytology. “Furthermore, we are working on a multidimensional study in anticancer. Through our neoantigen research service, Alfa Cytology identifies unique cancer-carrying genes by sequencing tumor cell genes to predict immune presentation affinity. Then we screen out characteristic neoantigens encoded, hoping to make a huge contribution to tumor immunotherapy.”

Scientists of Alfa Cytology work on tailored projects by diagnosing PC and identifying its biomarkers. The ultimate aim of the company is to develop new drugs that are more cost-effective, less toxic, and have higher efficacy and safety to meet the market’s needs. Alfa Cytology possesses a comprehensive understanding of the tumor immunological profile of PC, including intra-tumor heterogeneity, intersection with the tumor-microenvironment, and microenvironmental instability. Hence, it can help clients achieve precise and feasible development applications of biotech to enhance the safety and efficacy of such pharmaceutical innovation for PC.

About Alfa Cytology

Alfa Cytology is a contract research organization (CRO) that specializes in early discovery and preclinical studies. It was founded by experts and scientists and has grown from a small team to a larger one capable of developing new therapies for cancer treatment. Alfa Cytology provides comprehensive research services globally, helping individuals and organizations cost-effectively achieve success.